As one of the most common side effects of insulin treatment remains significant weight gain, combining it with leptin-neutralizing antibodies would restore leptin sensitivity and prove beneficial for the management of obesity in type 2 DM [135]. The gene discussed is LEP; the disease is obesity due to melanocortin 4 receptor deficiency.